1. Scrip
  2. >>Business

Shingrix Seen Replacing Zostavax In EU & US as Shingles Standard Of Care

 
• By Sten Stovall

Shingrix is likely to replace Merck & Co's Zostavax as the preferred shingles vaccine in the EU and US, following the GSK product’s approval in the US and recent positive opinion in the EU. Sales in major markets could approach $700m by 2025.

SC1801_Injection Target_701303299_1200.jpg
Shingrix Seen Replacing Zostavax as HZ standard of care vaccine for EU elderly • Source: Shutterstock

With US regulatory approval in hand and passage likely in Europe, GlaxoSmithKline PLC's Shingrix vaccine looks poised to displace Merck & Co. Inc.'s Zostavax (Zoster vaccine live, ZVL) in both regions for treating shingles in older people, analysts say.

The FDA last October approved Shingrix for the prevention of herpes zoster in adults at least 50 years of age based on a review of data from the ZOE-50 and ZOE-70 studies, and results from the Zoster-048 trial, which showed Shingrix

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.